Rigel Pharma Announces Results From Second FIT Phase 3 Study - Quick Facts

Rigel Pharmaceuticals, Inc. (RIGL) announced results for the second of two double-blind studies in the FIT Phase 3 clinical program for fostamatinib, an oral spleen tyrosine kinase or SYK inhibitor, in adult chronic/persistent immune thrombocytopenia (ITP).

from RTT - Biotech http://ift.tt/2ek65Xd
via IFTTT